143 related articles for article (PubMed ID: 24061455)
21. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors.
Zachariah RR; Schmid S; Buerki N; Radpour R; Holzgreve W; Zhong X
Obstet Gynecol; 2008 Oct; 112(4):843-50. PubMed ID: 18827127
[TBL] [Abstract][Full Text] [Related]
22. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
23. Free circulating DNA as possible tumour marker in colorectal cancer.
Boni L; Cassinotti E; Canziani M; Dionigi G; Rovera F; Dionigi R
Surg Oncol; 2007 Dec; 16 Suppl 1():S29-31. PubMed ID: 18024018
[TBL] [Abstract][Full Text] [Related]
24. Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease.
Schmidt B; Weickmann S; Witt C; Fleischhacker M
Ann N Y Acad Sci; 2008 Aug; 1137():207-13. PubMed ID: 18837948
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.
Marzese DM; Hirose H; Hoon DS
Expert Rev Mol Diagn; 2013 Nov; 13(8):827-44. PubMed ID: 24127721
[TBL] [Abstract][Full Text] [Related]
26. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker.
Ellinger J; Albers P; Müller SC; von Ruecker A; Bastian PJ
BJU Int; 2009 Jul; 104(1):48-52. PubMed ID: 19154496
[TBL] [Abstract][Full Text] [Related]
27. DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer.
Hanley R; Rieger-Christ KM; Canes D; Emara NR; Shuber AP; Boynton KA; Libertino JA; Summerhayes IC
Clin Cancer Res; 2006 Aug; 12(15):4569-74. PubMed ID: 16899603
[TBL] [Abstract][Full Text] [Related]
28. Can quantifying free-circulating DNA be a diagnostic and prognostic marker in oral epithelial dysplasia and oral squamous cell carcinoma?
Shukla D; Kale AD; Hallikerimath S; Yerramalla V; Subbiah V
J Oral Maxillofac Surg; 2013 Feb; 71(2):414-8. PubMed ID: 22749518
[TBL] [Abstract][Full Text] [Related]
29. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
[TBL] [Abstract][Full Text] [Related]
30. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.
Flamini E; Mercatali L; Nanni O; Calistri D; Nunziatini R; Zoli W; Rosetti P; Gardini N; Lattuneddu A; Verdecchia GM; Amadori D
Clin Cancer Res; 2006 Dec; 12(23):6985-8. PubMed ID: 17145818
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer.
Altimari A; Grigioni AD; Benedettini E; Gabusi E; Schiavina R; Martinelli A; Morselli-Labate AM; Martorana G; Grigioni WF; Fiorentino M
Am J Clin Pathol; 2008 May; 129(5):756-62. PubMed ID: 18426736
[TBL] [Abstract][Full Text] [Related]
32. Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological Classification.
Salvianti F; Giuliani C; Petrone L; Mancini I; Vezzosi V; Pupilli C; Pinzani P
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28672797
[TBL] [Abstract][Full Text] [Related]
33. Increased DNA integrity in colorectal cancer.
Leszinski G; Lehner J; Gezer U; Holdenrieder S
In Vivo; 2014; 28(3):299-303. PubMed ID: 24815830
[TBL] [Abstract][Full Text] [Related]
34. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
35. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M; Tzitzira A; Strati A; Sotiropoulou G; Sfikas C; Malamos N; Georgoulias V; Lianidou E
Clin Biochem; 2013 Feb; 46(3):235-40. PubMed ID: 23006792
[TBL] [Abstract][Full Text] [Related]
36. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
37. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
[TBL] [Abstract][Full Text] [Related]
38. Multiparametric analysis of cell-free DNA in melanoma patients.
Salvianti F; Pinzani P; Verderio P; Ciniselli CM; Massi D; De Giorgi V; Grazzini M; Pazzagli M; Orlando C
PLoS One; 2012; 7(11):e49843. PubMed ID: 23209607
[TBL] [Abstract][Full Text] [Related]
39. Quantification of Circulating Free DNA as a Diagnostic Marker in Gall Bladder Cancer.
Kumari S; Tewari S; Husain N; Agarwal A; Pandey A; Singhal A; Lohani M
Pathol Oncol Res; 2017 Jan; 23(1):91-97. PubMed ID: 27475647
[TBL] [Abstract][Full Text] [Related]
40. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study.
Hauser S; Zahalka T; Fechner G; Müller SC; Ellinger J
Anticancer Res; 2013 Oct; 33(10):4651-6. PubMed ID: 24123044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
